Larimar Therapeutics (LRMR) CEO receives 100,100 RSUs and 600,600-share option grant

Rhea-AI Filing Summary

Larimar Therapeutics President and CEO Carole Ben-Maimon reported equity awards dated January 26, 2026. She received 100,100 shares of Common Stock for no cash cost, structured as restricted stock units that each convert into one share upon settlement.

She was also granted a stock option for 600,600 shares of Common Stock at an exercise price of $3.60 per share. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to her continued service. After these grants, she directly holds 368,276 shares of Common Stock and 600,600 stock options, while several irrevocable family trusts for which she serves as trustee each hold 31,155 or 31,156 shares; she disclaims beneficial ownership of those trust shares except to any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEN-MAIMON CAROLE

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PA 19004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		100,100(1)	A	$0.00	368,276	D
Common Stock								31,155	I	By Trust(2)
Common Stock								31,155	I	By Trust(3)
Common Stock								31,156	I	By Trust(4)
Common Stock								31,156	I	By Trust(5)
Common Stock								31,156	I	By Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.6	01/26/2026		A		600,600		(7)	01/26/2036	Common Stock	600,600	$0.00	600,600	D

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Meadow Lainey Ben-Maimon ("Meadow Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Meadow Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.

3. Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Olivia Liat Stein ("Olivia Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Olivia Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.

4. Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Ella Bar Stein ("Ella Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Ella Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.

5. Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Romi Aleeza Stein ("Romi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Romi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.

6. Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Matzi Mark Ben-Maimon ("Matzi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Matzi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.

7. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

	/s/ Jennifer Johansson, Attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Larimar Therapeutics (LRMR) CEO Carole Ben-Maimon receive?

Carole Ben-Maimon received 100,100 shares of Common Stock via restricted stock units and a stock option for 600,600 shares at a $3.60 exercise price. Both awards were granted on January 26, 2026 as part of her compensation.

How do the new restricted stock units for Larimar (LRMR) CEO work?

Each restricted stock unit represents the right to receive one share of Larimar Common Stock upon settlement. The filing shows 100,100 RSU-based shares were granted to CEO Carole Ben-Maimon at no cash cost to her on January 26, 2026.

What are the vesting terms of Carole Ben-Maimon’s new Larimar stock option?

The 600,600-share stock option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over 36 months. Vesting requires Ben-Maimon’s continued service with Larimar Therapeutics through each applicable vesting date.

How many Larimar (LRMR) shares does Carole Ben-Maimon directly own after this Form 4?

Following the reported transactions, Carole Ben-Maimon directly owns 368,276 shares of Larimar Common Stock. This number reflects her direct holdings after the 100,100-share restricted stock grant reported as acquired for no cash consideration.

What trusts related to Carole Ben-Maimon hold Larimar Therapeutics shares?

Several irrevocable trusts for beneficiaries Meadow Lainey, Olivia Liat, Ella Bar, Romi Aleeza, and Matzi Mark hold between 31,155 and 31,156 Larimar shares each. Ben-Maimon serves as trustee and disclaims beneficial ownership except for any pecuniary interest.

Does this Larimar (LRMR) Form 4 show insider buying or selling in the market?

The Form 4 reports equity compensation grants: restricted stock units and a stock option with a $3.60 exercise price. The Common Stock and option awards were acquired at a stated price of $0.00 to the reporting person, rather than open-market purchases or sales.